Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022
The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.
You may also be interested in...
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.